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The chemokine CCL2 (MCP-1) has been identified as a prominent tumor-promoting factor in breast cancer. The major
source for CCL2 is in the tumor cells; thus, identifying the mechanisms regulating CCL2 release by these cells may
enable the future design of modalities inhibiting CCL2 secretion and consequently reduce tumorigenicity. Using cells
deficient in expression of glycosaminoglycans (GAGs) and short hairpin RNAs reducing heparan sulfate (HS) and
chondroitin sulfate (CS) expression, we found that intracellular HS and CS (=GAGs) partly controlled the trafficking of
CCL2 from the Golgi toward secretion. Next, we determined the secretion levels of GFP-CCL2-WT and GFP-CCL2-
variantsmutated in GAG-binding domains and/or in the 40s loop of CCL2 (45TIVA48).We have identified partial roles for
R18+K19, H66, and the 45TIVA48 motif in regulating CCL2 secretion. We have also demonstrated that in the absence
of R24 or R18+K19+45TIVA48, the secretion of CCL2 by breast tumor cells was almost abolished. Analyses of the
intracellular localization ofGFP-CCL2-mutants in theGolgi or the endoplasmic reticulum revealed particular intracellular
processes in which these CCL2 sequences controlled its intracellular trafficking and secretion. The R24, 45TIVA48 and
R18+K19+45TIVA48 domains controlled CCL2 secretion also in other cell types. We propose that targeting these
chemokine regions may lead to reduced secretion of CCL2 by breast cancer cells (and potentially also by other
malignant cells). Such a modality may limit tumor growth and metastasis, presumably without affecting general
immune activities (as discussed below).
Neoplasia (2014) 16, 723–740Introduction
Many recent studies provide evidence to the predominant roles played
by inflammatory mediators in dictating the progression of malignant
diseases. It is now generally accepted that inflammatory processes mostcommonly exert pro-tumorigenic effects and that the inflammatory
microenvironment has major impact in promoting metastasis [1–4].
The inflammatory chemokine CCL2 (known also as MCP-1) is
a prominent pro-cancerous inflammatory mediator, particularly in breast
cancer [5–14]. The chemokine is expressed by leukocytes and stroma cells at
the tumor site. However, the major source for CCL2 is in the breast cancer
cells themselves, while it is hardly expressed by normal breast epithelial cells;
moreover, in patients with breast cancer, high expression levels of CCL2
were correlated with advanced disease and early relapse [15–23]. Studies
performed in vivowith animalmodel systems of breast cancer havemodified
the expression/activities of CCL2 or its CCR2b receptor and have indicated
that this axis is directly and causatively responsible for breast tumor growth
and dissemination of the cancer cells to distant organs [22–29].
As a member of the chemokine superfamily of leukocyte chemoat-
tractants, CCL2 recruitsmyeloid cells and leads to high contents of tumor-
associated macrophages (TAMs) and myeloid-derived suppressor cells in
Table 1. The aa Composition of GFP-CCL2 WT and GFP-CCL2 Mutants Used in the Study.
The table denotes sequences of CCL2 WT and its mutated variants. Bold and underlined,
sequences that were mutated in each CCL2 variant compared to the WT chemokine. The numbers
indicate the position of the amino acids in the mature CCL2 protein. N′, amino terminus of CCL2.
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in the tumors, together with the direct angiogenic activities of CCL2
on endothelial cells, contributes to the elevated angiogenic profile
attributed to this chemokine [7,18,20,21,25,33–39]. In parallel, CCL2
promotes metastasis-related functions by acting directly on CCR2-
expressing tumor cells, giving rise to tumor cell migration and invasion,
to production of matrix metalloproteinases and to increased metastasis
[14,22,23,26–29,40–43].
In the malignancy context, the “point of no return” is the step
of CCL2 secretion, particularly from cancer cells, as they are the
major source for the chemokine in breast tumors. Once released, the
chemokine can induce all the above tumor-promoting functions by
acting on cells of the tumor microenvironment and on the cancer
cells. Inhibition of this crucial secretory step may halt many of the
pro-tumoral activities of CCL2, and limit its ability to promote tumor
growth and metastasis.
The aim of the current study was to identify intracellular components
and chemokine motifs that regulate the secretion of CCL2 by breast
tumor cells.Our published study indicated that in the chemokineCCL5,
the 40s loop 43TRKN46 sequence was absolutely required for the
secretion of this chemokine by breast tumor cells and by other cell types
as well [44]. In CCL5, the 43TRKN46 motif is the sequence mediating
the binding of the chemokine to extracellular glycosaminoglycans
(GAGs) [45,46], a process required for leukocyte extravasation in
inflamed tissues [47,48]. The GAG-binding capacity of 43TRKN46 was
found in our study to be relevant for processes of CCL5 secretion, as we
could show that CCL5 release by breast tumor cells was partly mediated
by intracellularly positioned GAGs [44]. Thus, CCL5 secretion was
mediated by interactions between GAGs and the GAG-binding
43TRKN46 motif, located in the 40s loop of the chemokine. Our
research on the control of CCL5 secretion by its 40s loop and by GAGs
has provided mechanistic views that extended previously published
findings on the roles of the 40s loop in sorting of CXCL8 andCXCL4 to
endothelial Weibel-Palade bodies and granules, respectively [49,50].
To follow on the above, we now asked the following questions: 1) Do
intracellular GAGs regulate the secretion of CCL2? If so, which GAGs are
involved in this process and towhat extent do they affect it? 2)What are the
CCL2motifs that control its secretion? Does the process depend onGAG-
binding domains of CCL2 and/or its 40s loop (=45TIVA48)? Here, it is
important to indicate that while CCL5 binds to GAGsmainly through the
40s loop, in CCL2 the situation ismore complex: CCL2 binding to GAGs
is mediated by several short amino acid (aa) sequences that are distributed
along the chemokine, forming a GAG-binding sheet when quaternary
structures are established by several CCL2 molecules [51,52].
The findings obtained in our current research identify the roles
of intracellular GAGs and specific chemokine domains in regulating
the intracellular trafficking and secretion of CCL2 by breast tumor
cells. These observations open new opportunities for blocking the
secretion of endogenous CCL2 by breast cancer cells and are thus of
major clinical relevance in breast cancer and potentially also in other
malignant diseases.
Materials and Methods
Cell Cultures
Human breast adenocarcinoma MDA-MB-231 cells were grown in
Dulbecco's modified Eagle's medium (DMEM) supplemented with
10% fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin,
100 μg/ml streptomycin, and 250 ng/ml amphotericin (all purchasedfrom Biological Industries, Beit Haemek, Israel). In this study, we used
two spontaneous variants of MDA-MB-231 cells, expressing either low
or high levels of endogenous CCL2 [22,27,40,41,53] (the latter cells
were kindly provided byDrGilles, University of Liège, Liège, Belgium).
Human embryonic kidney–293 (HEK 293) cells were maintained in
DMEM as above. Chinese hamster ovary (CHO) cells were also used in
the study (kindly provided by Prof. Vlodavsky, Technion,Haifa, Israel):
CHO-K1 and CHO-pgsA-745 cells were cultured in DMEM and
Roswell Park Memorial Institute (RPMI) medium, respectively,
supplemented as above [with the addition of 1 mM sodium pyruvate
(Biological Industries)]. Before different experimental procedures, the
various cell lines were transferred to their corresponding serum-free
media, except for HEK 293 cells that were continuously grown in their
serum-including medium.
Chemokine Sequences
The vector used in the analyses of this study was pEGFP-N1,
designed to express wild type (WT) or mutated CCL2 (Table 1). The
constructs of WT and mutated CCL2 were produced by polymerase
chain reaction, and the sequences of all chemokines (WT and mutated)
were validated by full-length sequencing.
Bioinformatics Analyses of CCL2 Mutants
To predict the appropriate folding of mutated CCL2 proteins, an
ab initio protocol was applied, which predicts the structure of a
protein based on its sequence. Models were built using Rosetta 3.1
AbinitioRelax protocol, with protein structure prediction using
Rosetta [54]. The final models presented were chosen out of
10,000 decoys, based on their lowest score. The models were further
assessed using the MolProbity web server [55]. The model structures
of CCL2 mutants (Table 1) were superimposed on the published X-
ray structure of CCL2-WT (PDB 1DOK [56]). Positions 1 to 13
were not shown in the relevant figures because the mutated
chemokines were modeled as monomers, whereas the published X-
ray structure of CCL2-WT was of a dimer, in which the N′ is
differently organized compared to the monomer. Positions 70 to 76
were not shown because no coordinates were available in the X-ray
structure of CCL2-WT.
Transfection by GFP-CCL2 Constructs and Determination of
Transfection Yields
The different cell types were transiently transfected with constructs
of GFP-CCL2 WT or GFP-CCL2-mutants (Table 1) using MP-100
MicroPorator (Digital Bio, Seoul, Korea; according to the manufac-
turer’s instructions) or by ICAFectin TM 441 DNA transfection
Neoplasia Vol. 16, No. 9, 2014 CCL2 secretion: GAGs and chemokine motifs Lebel-Haziv et al. 725reagent (Cat. No. ICA441; In-Cell-Art, Nantes, France; according to the
manufacturer’s instructions). Transfection outcome was evaluated by
flow cytometry analyses (FACS). To this end, the cells were washed with
phosphate-buffered saline supplemented with 0.02% sodium azide, and
the expression ofGFPwas determinedwith a BectonDickinson FACSort
(Mountain View, CA) using the CellQuest software.
Down-Regulation of Heparan Sulfate and Chondroitin Sulfate
Expression by Short Hairpin RNAs Targeting Exostosin
Glycosyltransferase or Chondroitin Sulfate Synthase
Heparan sulfate (HS) and chondroitin sulfate (CS) are saccharides;
thus, they could not be downregulated directly by short hairpin
RNAs (shRNAs) but rather by targeting key enzymes involved in
their synthesis, namely, exostosin glycosyltransferase (EXT) and
chondroitin sulfate synthase (CHSY), respectively. Down-regulation
of EXT or CHSY expression was performed by lentiviral infection
with shRNA. Several different shRNAs were assayed and the most
effective ones were chosen for use throughout the study. In the case
of EXT, down-regulation of EXT2 was performed by a combination
of two different shRNA clones (both from Sigma-Aldrich, Rehovot,
Israel): 1) Cat. No. SHCLNG-NM_000401.1-2839s1c1 and
2) Cat. No. SHCLNG-NM_000401.x-2366s1c1. In the case of
CHSY, down-regulation of CHSY1 was assumed by shRNA Cat. No.
SHCLNG-NM_014918.3-1964s1c1 (Sigma-Aldrich). Following
infection, selection was performed with 4 μg/ml puromycin (A.G.
Scientific, San Diego, CA). Then, the cell population was used as a
whole to prevent bias toward specific cell clones. Control cells were
infected with control shRNA vectors (Sigma-Aldrich) carrying similar
antibiotic resistance. Down-regulation of EXT2 or CHSY1 was
verified by reduced expression of HS or CS in the cells, using confocal
analyses (please see below).
Determination of CCL2 Secretion by enzyme-linked
immunosorbent assay (ELISA)
Different cell types have undergone transfection or infection as
described above and then were grown in serum-free medium for
24 to 48 hours (except for HEK 293 cells, as mentioned above).
In specific experiments, MDA-MB-231 cells were treated with brefeldin
A (BFA; 5–10 μg/ml; Cat. No. B7651; Sigma-Aldrich) for 2 hours at
37°C before ELISAs. BFA did not affect cell viability.
In all cases, human CCL2 levels in cell conditioned medium were
determined by ELISA using standard curves with rhCCL2 (Cat. No.
300-04; PeproTech, Rehovot, Israel), at the linear range of absorbance.
The following antibodies were used (all from PeproTech): coating
rabbit polyclonal antibodies (Cat. No. 500-p34); detecting biotinylated
rabbit polyclonal antibodies (Cat. No. 500-P34Bt). After the addition
of streptavidin-horseradish peroxidase (HRP; Cat. No. 016-030-084;
Jackson ImmunoResearch Laboratories,West Grove, PA), the substrate
TMB/E solution (Chemicon, Temecula, CA) was added. The reaction
was stopped by the addition of 0.18 MH2SO4 and the absorption was
measured at 450 nm. In parallel, cells were removed by trypsinization
and counted by trypan blue exclusion (Cat. No. 03-102-1B; Biological
industries), and the ELISA results were presented as ng/107 cells.
Determination of CCL2 Expression by Western Blot Analysis
MDA-MB-231 cells were transiently transfected with constructs
of GFP-CCL2 WT, GFP-CCL2 mutants, or control GFP vector.
Cells were lysed in RIPA lysis buffer and immunoprecipitation
was performed with mouse monoclonal IgG antibody against GFP(Cat. No. M048-3; Covance, Princeton, NJ; MBL International,
Woburn, MA). Immunoprecipitation was followed by conventional
Western blot (WB) procedure, using rabbit IgG polyclonal antibodies
against human CCL2 (Cat. No. 500-p34; PeproTech). HRP-conjugated
goat anti-rabbit IgG antibodies (Cat. No. 111-035-003; Jackson
ImmunoResearch Laboratories) were used as secondary antibodies.
In parallel, blots were reacted with mouse monoclonal IgG
antibodies against GFP and then with secondary goat anti-mouse
antibodies (Cat. No. 115-035-166; Jackson ImmunoResearch
Laboratories. Data not shown). The membranes were subjected to
enhanced chemiluminescence.
Confocal Analyses
Endogenous CCL2 was detected in the cells by staining with
monoclonal IgG antibodies against human CCL2 (Cat. No. 500-
M71; PeproTech) and then with fluorescein isothiocyanate–conjugated
goat anti-mouse IgG antibodies (Cat. No. 115-095-003; Jackson
ImmunoResearch Laboratories).
In experiments using GFP-CCL2 constructs (WT or mutated), the
transfected cells were grown in growth medium on coverslips for
24 hours and then in serum-free medium for another 24 hours at
37°C. Cells were fixed with 8% paraformaldehyde (Cat. No. 1.04005;
Merck KGaA, Darmstadt, Germany), permeabilized by 0.2% Triton
(Cat. No. X-100; Sigma-Aldrich), and blocked with 2% BSA (Cat.
No. 0332-TAM; Amresco, Solon, OH). To determine the localization
of GFP-CCL2 WT or GFP-CCL2 mutants in the Golgi, a vector
expressing the Golgi marker α-mannosidase IB, tagged
by hemagglutinin (HA), was expressed by transfection in the cells.
HA was detected by rabbit IgG antibodies against HA (Cat. No. sc-
805; Santa Cruz Biotechnology, Santa Cruz, CA) and then with
DyLightTM 549–conjugated AffiniPure goat anti-rabbit IgG anti-
bodies (Cat. No. 111-505-144; Jackson ImmunoResearch Laborato-
ries). To determine the localization of GFP-CCL2WT or GFP-CCL2
mutants in the endoplasmic reticulum (ER), staining was performed
with rabbit IgG antibodies against calnexin (Cat. No. sc-11397; Santa
Cruz Biotechnology) and then with DyLightTM 549–conjugated
AffiniPure goat anti-rabbit IgG antibodies (as above). Quantification
of co-localization of GFP-CCL2 WT or GFP-CCL2 mutants with
markers of the Golgi or the ER was performed by Slidebook TM or
ImageJ software, respectively, applied on a large number of cells.
In parallel, experiments were performed to determine the co-localization
of GFP-CCL2 WT with GAGs (HS and CS) in the Golgi. In these
experiments, MDA-MB-231 cells were transiently transfected by a
construct expressing GFP-CCL2 WT and simultaneously with a vector
expressing the Golgi marker α-mannosidase IB, tagged by HA. The cells
were stained with rabbit IgG antibodies against HA (as above), followed by
DyLightTM 549–conjugated AffiniPure goat anti-rabbit IgG antibodies
(as above) andwithmouse IgM antibodies againstHS orCS (HS:Cat.No.
370255; SEIKAGAKUCorporation, Tokyo, Japan; CS: Cat. No. c-8035;
Sigma-Aldrich), followed by Alexa Fluor 647 goat anti-mouse IgM
antibodies (Cat. No. A-21238; Invitrogen, Carlsbad, CA).
To examine the expression levels of HS and CS in MDA-MB-231
cells that were stably infected with EXT2 shRNAs or CHSY1 shRNA
or in CHO cells, the cells were stained with mouse IgM antibodies
against HS or CS, followed by Alexa Fluor 647 goat anti-mouse IgM
antibodies, as above.
In all the experiments, negative controls included cell staining
by isotype-matched non-relevant antibodies, followed by secondary
antibodies, as appropriate (data not shown). Coverslips were mounted
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Bridge International, Mukilteo, WA) and read by ZEISS LSM-510
confocal microscopy.
Statistical Analyses and Data Presentation
Statistical analyses were done using Student's t tests. Values of
P b .05 were considered statistically significant. Adjustment for
multiplicity of comparisons was done using the Benjamini-Hochberg
procedure. Using this procedure, all the significant results that were
presented in the manuscript remained statistically significant after
correcting for their multiplicity. Each type of ELISA experiment was
repeated at least three independent times with reproducible results
and the findings were presented as a representative experiment of
these similar repeats (except for BFA results, because of technical
reasons). The confocal pictures are representatives of many pictures
that were taken in at least three independent experiments and their
quantitative results were presented as mean ± standard deviation (SD)
of values obtained from many pictures.
Results
The Trafficking of CCL2 from the Golgi toward Secretion
Partly Depends on Intracellular GAGs
In this study, our aim was to determine the mechanisms regulating the
secretion of CCL2 by breast tumor cells. To this end, we used a cell
system that is conventionally used in breast cancer studies, based on
MDA-MB-231 breast tumor cells. Two spontaneous variants of MDA-
MB-231 have been described in the literature, one expressing
endogenously low levels of CCL2 (to be called herein “MDA-CCL2-
low” cells [22,27,53]) and the second expressing high levels of the
chemokine (“MDA-CCL2-high” cells [40,41]). In our study, the use of
such two variant cell lines has enabled us to optimally address different
aspects of the study, as follows: 1) MDA-CCL2-low cells—These cells
provided an excellent platform for clearly comparing the secretion
properties of different CCL2 variants by overexpressing GFP-CCL2WT
or GFP-CCL2mutants. In addition, using the GFP signal as readout, we
could decipher the localization of CCL2WTand ofGFP-CCL2mutants
in the Golgi and ER, with high-quality confocal analyses. 2) MDA-
CCL2-high cells—With these cells, we could identify in great detail the
mechanisms regulating the secretion of endogenous CCL2 by using
pharmacological inhibitors or shRNAs.
To establish the MDA-CCL2-low–based system in our study, the
cells have undergone transfection by a GFP-CCL2 WT construct
(FigureW1A1; GFP expressed at the carboxyl terminus of the molecule;
Table 1), leading to productive secretion of the chemokine by the cells
(FigureW1A2). Following overexpression ofGFP-CCL2WT, the levels
of CCL2WT in cell supernatants were generally at the range of ~80 to
500 ng/107 cells, depending on transfection yields. These CCL2 levels
agreed well with the levels of CCL2 generally produced endogenously by
MDA-CCL2-high cells (see below). GFP-CCL2 WT has gained a
vesicular phenotype in the MDA-CCL2-low cells transfected by the
construct (Figure W1B1), which was similar to the phenotype of
endogenous CCL2 in MDA-CCL2-high cells (Figure W1B2). In both
cell types—MDA-CCL2-low cells transfected by GFP-CCL2 WT and
MDA-CCL2-high cells—CCL2 had a vesicular distribution and a
typical Golgi localization (as will be shown later by more specific
analyses), standing in line with the secretory nature of the chemokine.
To identify the intracellular path taken by CCL2 WT on its way
toward secretion, we first determined the co-localization of transfectedGFP-CCL2 WT with Golgi or ER markers in the transfected MDA-
CCL2-low cells. Definite positioning of the chemokine in theGolgi was
identified by substantial co-localization of GFP-CCL2 WT with the
Golgi marker α-mannosidase IB (Figure 1A) and relatively limited co-
localization with the ER marker calnexin (Figure 1B). These results
suggested that CCL2WT takes the ER-to-Golgi route in its way toward
secretion, as do many secreted proteins. Indeed, specific inhibition of
ER-to-Golgi trafficking by BFA in MDA-CCL2-high cells has led to
substantial reduction, of 70.9 ± 15.2% in CCL2 secretion in the
different experiments, indicating that the chemokine takes the ER-to-
Golgi route toward secretion (Figure 1C).
To determine the roles of intracellular GAGs in the secretion of
CCL2WT, we first asked whether the chemokine was co-localized with
GAGs intracellularly. Published reports indicated that HS and CS are
the two most abundant GAGs expressed by MDA-MB-231 cells and
that the two GAGs share the ability to bind CCL2 [57–59]. In our
analyses of GFP-CCL2 WT in transfected MDA-CCL2-low tumor
cells, we found that CCL2was highly co-localized withHS and with CS
(Figure 2, A and B, respectively). In parallel, we found preferential
expression of HS and CS in the Golgi; consequently, definite co-
localization of GFP-CCL2WT with HS and CS in the Golgi has been
revealed (Figure 2, A and B, respectively). Taken together, all of the
above findings indicate that CCL2 WT exits the ER and reaches the
Golgi. The results also suggest that CCL2 associates with GAGs in the
Golgi and then proceeds toward secretion.
To further address the involvement of GAGs in CCL2 secretion, we
have taken advantage of the well-studied CHO cell system consisting of
variants selected for mutations in GAG expression [60]. Specifically, in
this study, we used 1) CHO cells expressing normal levels of GAGs,
originally termed CHO-K1, which for the sake of clarity were given the
name CHO-GAG+++ in our current study, and 2) CHO cells that are
almost completely deficient in expression of all GAGs due to substantial
reduction in the expression of xylosyltransferase, the enzyme that
initiates the process of GAG synthesis [61]. In the past, it was shown
that these latter CHO-deficient GAG cells (originally termed CHO-
pgsA-745) did not have a general defect in secretion [62]. In line with
the original characterization of these two cell lines in the literature, we
found that the CHO-deficient GAG cells exhibited almost complete
inhibition in expression of HS and CS (Figure W2A).
Using the CHO cell–based system, we asked whether deficiency in
GAG expression would affect the intracellular localization and
secretion of CCL2. Because GAGs are synthesized mainly in the
Golgi [63–65], we expected that the ER-to-Golgi step will not
depend on GAGs, and thus, the levels of CCL2 localization in the
Golgi will be similar in CHO-GAG+++ cells and in CHO-deficient
GAG cells. Indeed, following the expression of GFP-CCL2 WT
(Figure W2B), the extent of CCL2 positioning in the Golgi was
similar in the two cell types (Figure 3, A–C). However, in the absence
of GAGs, the secretion of CCL2 WT was partly and significantly
inhibited (Figure 3D), showing an average of 59.4 ± 16.2%
reduction in CCL2 WT secretion in the different experiments.
Taken together, these results indicate that GAGs partly regulate the
process of CCL2 secretion and suggest that GAGs control the
intracellular trafficking of CCL2 at the post-Golgi stage.
HS and CS Partly Mediate the Process of CCL2 Secretion by
Breast Tumor Cells
The above findings, demonstrating that the secretion of CCL2WT
required partial involvement of GAGs, led us to ask if the secretion of
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Figure 1. CCL2 WT takes the ER-to-Golgi route toward secretion. MDA-CCL2-low cells were transfected to express GFP-CCL2 WT.
Additional characteristics of the transfected cells are shown in Figure W1. (A and B) After 48 hours, the intracellular localization of CCL2
was determined by confocal analyses of the GFP signal. (A) GFP-CCL2 WT expression in the Golgi. In parallel to expression of GFP-CCL2
WT, the expression of the Golgi marker α-mannosidase IB was determined by antibodies. (B) GFP-CCL2 WT expression in the ER. In
parallel to expression of GFP-CCL2 WT, the expression of the ER marker calnexin was determined by antibodies. In A and B, negative
controls included staining by non-relevant isotype-matched antibodies (data not shown). The results are representatives of many pictures
thatwere taken inn N 3 independent experiments. Bar, 10 μm. (C) The secretion ofCCL2 required for ER-to-Golgi transport of the chemokine.
The cells were treated by BFA (5-10 μg/ml; 2 hours), and the levels of CCL2 in cell supernatants were determined by sandwich ELISAs, at the
linear range of absorbance. Untreated cells (control) were given the value of 1. C presents normalized results of a representative experiment
of n N 3 independent experiments, where **P b .01 comparing between BFA-treated and untreated cells. The P value was calculated from
the original test values, before normalization. Inhibition levels by BFA were 70.9 ± 15.2% in the different experiments.
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HS and CS. To generate such cells, we chose to take the shRNA
approach. Because HS and CS are saccharides, we could not target
them directly but rather had to target key enzymes that synthesize
them. Thus, as a general outline, we expressed in MDA-CCL2-high
cells different shRNAs that targeted HS- or CS-generating enzymes.
The relevant readout in this part of the study was extensive and
marked inhibition of the actual expression of HS or CS in the cells,
analyzed by the most appropriate tool of specific antibodies directed
to HS and CS (as saccharides, the GAGs could not be analyzed at the
mRNA level; WB studies were expected to be problematic because of
the relative low binding affinity of GAGs to proteins). Following the
infection of the cells by the different shRNAs, the analyses of CCL2secretion were continued only with those shRNAs that indeed gave
rise to the desired extensive and marked inhibition of HS (by shRNAs
to EXT2; Figure 4A1) or of CS (by shRNA to CHSY1; Figure 4A2)
expression. Taking this approach, we could show that the secretion of
endogenous CCL2 was partly reduced in the absence of HS and CS,
by an average of 37.6 ± 6.2% and 36.1 ± 3.8%, respectively, in the
different experiments (Figure 4, B1 and B2).
These findings indicate that each of the two predominant
GAGs expressed in MDA-MB-231 cells partly affects the secretion
of CCL2 WT, standing in line with the partial involvement of GAGs
in CCL2 secretion that was revealed for GFP-CCL2 WT in CHO
cells. Here, it is important to indicate that in the course of these
studies we found out that complex co-regulatory pathways exist
B) CCL2-WT with CS in Golgi
A) CCL2-WT with HS in Golgi
Overlay 
Overlay 
GFP-CCL2-WT Golgi
GolgiGFP-CCL2-WT
HS
CS
Figure 2. CCL2 WT is localized with HS and CS in the Golgi. MDA-CCL2-low cells were transfected to express GFP-CCL2 WT. After
48 hours, the intracellular localization of the chemokine was determined by confocal analyses of the GFP signal. (A) Co-localization
of GFP-CCL2 WT with HS in the Golgi. The expression patterns of HS and of the Golgi marker α-mannosidase IB were determined
by antibodies. (B) Co-localization of GFP-CCL2WTwith CS in theGolgi. The expression patterns of CS and of theGolgimarker α-mannosidase
IBwere determined by antibodies. In both parts of the figure, negative controls included staining by non-relevant isotype-matched antibodies
(data not shown). The results are representatives of many pictures that were taken in n N 3 independent experiments. Bar, 10 μm.
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to run experiments in which both HS and CS were downregulated
simultaneously by shRNAs to EXT2+CHSY1.
The Secretion of CCL2 WT Depends on Its GAG-Binding
Domains and on Its 40s Loop
The results described so far indicate that GAGs partly mediate the
secretion of CCL2. The binding of CCL2 to GAGs has been studied
extensively in the past. In the presence of heparin oligosaccharides,
CCL2 tetramers were formed, where a continuous ring of basic
residues encircled the tetramer and created a positively charged
surface that could bind GAGs. The integration of several reports
indicated that R18, K19, R24, and K49 constituted the primary
GAG-binding domains of CCL2 and suggested that K58 and H66
also participated in GAG binding although to a lesser extent [51,52].
To follow on this information, we designed CCL2 variants mutated
in GAG-binding aa, including the R18+K19 pair that has been
extensively studied for its roles in GAG binding and R24, K49, K58 or
H66 (themutants eventually used in the study are shown inTable 1). In
parallel, we designed mutants that carried mutations in different
combinations of two to four of these amino acids. For further analysis,
we have used only those mutants whose bioinformatics Three-
Dimensional (3D) structure modeling (Figure W3) and published
nuclear magnetic resonance (NMR) analyses [51,66] have revealed
structural integrity. These mutants included R18A+K19A, R24A and
H66A, whose aa sequences are shown in Table 1.
As mentioned above, we have also addressed the role of the 40s
loop of CCL2 in regulating the secretion of the chemokine. Here, we
focused on the 45TIVA48 domain in CCL2 that is equivalent to the
43TRKN46 motif that regulated CCL5 secretion by breast tumor cells
and other cell types as well [44]. Correct folding of the 45TIVA48
mutant of CCL2 was predicted by modeling (Figure W3),and thus, a TIVA mutant (45AAAA48) was generated, to be named
TIVA−− (Table 1). To analyze the cooperativity between GAG-binding
domains and the 40s loop of CCL2, we also generated an R18A+K19A
+TIVA−− mutant, which based on bioinformatics modeling carried an
intact 3D structure (Figure W3 and Table 1).
Overall, the study included five CCL2 mutants: R18A+K19A,
R24A, H66A, TIVA−−, and R18A+K19A+TIVA−−. All mutants
were tagged by GFP in their carboxyl terminus as was previously
done for the WT chemokine, GFP-CCL2 WT (Table 1). Following
transfection to MDA-CCL2-low cells, the molecular weights (MWs)
of the WT and mutated forms of CCL2 were determined by WB
analyses following immunoprecipitation by GFP-directed antibodies.
Figure W4 demonstrates the results obtained by reacting the
membrane with polyclonal antibodies against CCL2; in general,
similar results were obtained by reacting the membrane with
monoclonal antibodies against GFP (data not shown). The WB
results indicated that 1) high CCL2 expression was detected only
after transfection of MDA-CCL2-low cells by GFP-CCL2 WT,
whereas cells transfected by the control empty GFP vector did not
show the expression of the chemokine; 2) GFP-CCL2 WT
migrated in the expected MW of ~38 to 40 kDa (27 kDa of
GFP + ~15 kDa of glycosylated CCL2), in two bands that probably
represent the different glycosylation forms of CCL2 previously
reported by others [67–69]; (3) all five GFP-CCL2 mutants
migrated in the gel in the same two forms found for GFP-CCL2
WT, thus assuring their correct MWs and structures. These WB
analyses, together with the bioinformatics and published NMR
studies mentioned above, suggested that the CCL2 mutants could
provide a solid platform for studying the roles of CCL2 domains in
regulating its secretion.
After assuring the expression of GFP-CCL2WT and the five GFP-
CCL2 mutants in MDA-CCL2-low cells, the following experimental
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that the expression levels of the mutated chemokines were similar to
those of the WT chemokine in each experiment (representative
experiments are shown in Figure W5); 2) CCL2 secretion was
determined by ELISAs by the same antibodies that were used in the
WB analyses (WB shown in Figure W4); 3) CCL2 localization in the
Golgi and in the ER was determined qualitatively and quantitatively
by confocal analyses.
Taking the above approach, we began this part of the study by
analyzing the R18A+K19A mutant. The secretion of this mutant by the
tumor cells was inhibited by an average of 51.1 ± 13.7%, obtained in the
different experiments comparing it to the WT chemokine (Figure 5A
and Table 2). As shown previously (Figures 1A and 2), the GFP-CCL2
WT was highly localized in the Golgi, with only sparse expression
in the ER. In comparison to the WT chemokine, the localization
of GFP-CCL2-R18A+K19A was reduced by 59% in the Golgi and
increased by 1.62-fold in the ER (Figure 5, B and C, and Table 2).0
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GFP-CCL2-WT GolgiThe analyses of the GFP-CCL2-R24A mutant have shown more
prominent inhibition in secretion, reaching an average of 85.6 ± 2.3%
reduction compared to the GFP-CCL2WT (Figure 6A), indicating that
R24 is a key determinant of CCL2 secretion. In comparison to the WT
chemokine, the GFP-CCL2-R24A variant has shown 55% inhibition in
Golgi localization and 1.67-fold elevation in ER localization (Figure 6, B
andC, andTable 2). In contrast, theGFP-CCL2-H66Amutant has been
distributed in the cells in a manner totally similar to that of GFP-CCL2
WT; nonetheless, the mutation in H66 has led to 46.1 ± 15.8%
inhibition in its secretion (Figure 7 and Table 2).
To follow the above results with the GAG-binding domain
mutants, we have determined these same characteristics for the GFP-
CCL2-TIVA−− mutant of the 40s loop. Giving rise to substantial
inhibition of 70.2 ± 4.3% in secretion by the tumor cells in the
different experiments, the Golgi localization of this mutant was
considerably reduced (by 63%) and the mutant had increased presence
of 1.43-fold in the ER compared to the GFP-CCL2 WT chemokine
(Figure 8 and Table 2). The experiments with the combined GFP-
CCL2-R18A+K19A+TIVA−− mutant showed almost complete inhi-
bition of secretion, at the level of 93.3 ± 9.3% in the different
experiments. In parallel, the localization of this mutated CCL2 in the
Golgi was reduced by 60% and its ER localization was elevated by 1.73-
fold (Figure 9 and Table 2).
To conclude, the overall results obtained in this part of the study
(summarized in Table 2) have identified two CCL2 domains that had
particular importance in regulating the secretion of the chemokine.
These were the R24 aa and the combination of R18+K19+45TIVA48
sequences. The mutation of these two domains gave rise to inhibition
of ~90% in CCL2 secretion. In parallel, the R18+K19 motif alone, the
40s loop on its own (45TIVA48), and the H66 aa had only partial roles
in regulating the secretion of CCL2. Except for H66 that had normal
intracellular localization in Golgi and ER, all other CCL2 mutations
(R24A, R18A+K19A, TIVA−−, and R18A+K19A+TIVA−−) hadFigure 3. Intracellular GAGs are partly required for CCL2 secretion
and for the transport of CCL2 WT from the Golgi toward secretion.
CHO-GAG+++ cells and CHO-deficient GAG cells were transfected
to express GFP-CCL2WT. Additional characteristics of the two CHO
cell types are shown in Figure W2. (A and B) Localization of GFP-
CCL2 WT in the Golgi of CHO-GAG+++ and of CHO-deficient GAG
cells, determined by confocal analyses of the GFP signal. In parallel
to expression of GFP-CCL2WT, the expression of the Golgi marker
α-mannosidase IBwas determined by antibodies. (A) The localization
of GFP-CCL2 WT in the Golgi of CHO-GAG+++ cells. (B) The
localization of GFP-CCL2WT in theGolgi of CHO-deficient GAG cells.
In A and B, the negative controls included staining by non-relevant
isotype-matched antibodies (data not shown). The results are
representatives of many pictures that were taken in n N 3 indepen-
dent experiments. Bar, 10 μm. (C) Quantitative analyses of the
co-localization obtained between GFP-CCL2 WT and the Golgi
marker α-mannosidase IB in CHO-GAG+++ and in CHO-deficient
GAG cells, performed by the Slidebook program. In C, the results
are based on analyses of many pictures that were taken in n N 3
independent experiments and are presented as mean ± SD, where
the values of CHO-GAG+++ cells were given the value of 1. NS, not
significant. (D) The secretion of GFP-CCL2 WT by CHO-GAG+++
cells and CHO-deficient GAG cells. The levels of CCL2 in cell
supernatants were determined by sandwich ELISAs, at the linear
range of absorbance. **P b .01 comparing between CCL2 secretion
levels in CHO-GAG+++ cells versus CHO-deficient GAG cells, with
inhibition levels of 59.4 ± 16.2% in the different experiments. In
D, the results are representatives of n N 3 independent experiments.
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Figure 4. HS and CS partly mediate the secretion of CCL2 by breast tumor cells. MDA-CCL2-high cells were infected by shRNAs directed
against the enzymes that synthesize HS or CS or by control non-relevant shRNAs. After 48 hours, the expression of HS or CS was
determined, and in parallel, the secretion of endogenous CCL2 was evaluated. (A) Down-regulation of HS expression (A1) or CS
expression (A2) after infection by shRNA for EXT2 (A1) or for CHSY1 (A2). The shRNAs were selected out of several shRNAs that were
tested for their ability to downregulate HS or CS expression. HS or CS expression was determined by antibodies using confocal analyses.
Negative controls included cells transfected by non-relevant shRNAs and staining by non-relevant isotype-matched antibodies (data not
shown). In A, the results are representatives of many pictures that were taken in n N 3 independent experiments. Bar, 10 μm. (B) The
levels of CCL2 in cell supernatants were determined by sandwich ELISA in the linear range of absorbance, in cells expressing shRNAs for
EXT2 (B1) or shRNA for CHSY1 (B2). *P b .05 and **P b .01 comparing cells transfected with control shRNA and shRNAs for EXT2 or
CHSY1. The inhibition levels in cells expressing shRNA downregulating EXT2 were 37.6 ± 6.2%, and for shRNA downregulating CHSY1,
they were 36.1 ± 3.8%. In B, the results are representatives of n N 3 independent experiments.
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The implications of these findings will be addressed further below, in
the Discussion section.
The Regulation of CCL2 Secretion by Its GAG-Binding
Domains and 40s Loop in Other Cells
The above findings have identified specific CCL2 domains that
control the secretion of CCL2 in breast tumor cells. To follow these
results, we asked how general is the ability of the different CCL2
domains to regulate CCL2 secretion. Specifically, we asked if the R18
+K19, R24, H66, 45TIVA48 and R18+K19+45TIVA48 domains
regulate CCL2 secretion not only in breast tumor cells but also in other
cell types. To address this question, we expressed all five mutants
in native cells that were not modified in GAG expression, namely,
CHO-GAG+++ and HEK 293 cells (validation of transfection yields
are shown in Figures W6 and W7, respectively).
The analyses of Figure 10 indicate that the different CCL2
chemokine motifs regulated CCL2 secretion in CHO-GAG+++ cells
in a pattern similar to the one revealed in breast tumor cells (Figure 10Avs Figures 5–9, respectively; Table 2 vs Table 3). In HEK 293 cells, the
CCL2 variants GFP-CCL2-R24A, GFP-CCL2-TIVA−−, and GFP-
CCL2-R18A+K19A+TIVA−− demonstrated inhibitory characteristics
similar to those in breast tumor cells and in CHO-GAG+++ cells
(Figure 10B vs Figures 6, 8, and 9; Table 2 vs Table 3). In contrast, the
mutations in R18+K19 and H66 were hardly inhibitory in HEK 293
cells, as indicated by the fact that the secretion of GFP-CCL2-R18A
+K19A and of GFP-CCL2-H66A were minimally reduced compared
to GFP-CCL2WT (Figure 10B vs Figures 5 and 7; Table 2 vsTable 3).
Thus, the intracellular components interacting with R24, 45TIVA48
and R18+K19+45TIVA48 were generally shared by the different cell
types, while those associating with H66 and R18+K19 alone
were more cell-specific (effective only in breast tumor cells and
CHO-GAG+++ cells).
Discussion
CCL2 is an inflammatory chemokine that exerts prominent pro-tumoral
effects in breast cancer and in numerous other malignancies. Many lines
of evidence indicate that following its release by breast tumor cells, CCL2
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Figure 5. The secretion of GFP-CCL2-R18A+K19A by breast tumor cells is partly inhibited, and the mutated chemokine shows reduced
propensity for Golgi localization. MDA-CCL2-low cells were transfected to express GFP-CCL2 WT or GFP-CCL2-R18A+K19A. Similar
expression levels of GFP-CCL2-R18A+K19A, compared to GFP-CCL2 WT, were validated by FACS analyses (Figure W5A). (A) The levels
of CCL2 in cell supernatants were determined 48 hours following transfection by sandwich ELISAs, at the linear range of absorbance.
In A, the results are representatives of n N 3 independent experiments. (B) The expression of GFP-CCL2-R18A+K19A versus GFP-CCL2
WT in the Golgi was determined on the basis of the GFP signal, combined with antibodies to the Golgi marker α-mannosidase IB, using
confocal analyses. Negative controls included staining by non-relevant isotype-matched antibodies (data not shown). Determination
of localization was performed qualitatively (B1) and quantitatively by the Slidebook program (B2). Bar, 10 μm. (C) The expression of GFP-
CCL2-R18A+K19A versus GFP-CCL2 WT in the ER was determined on the basis of the GFP signal combined with antibodies to the ER
marker calnexin, using confocal analyses. Negative controls included staining by non-relevant isotype-matched antibodies (data not
shown). Determination of localization was performed qualitatively (C1) and quantitatively by the ImageJ program (C2). Bar, 10 μm. In B1
and C1, the results are representatives of many pictures that were taken in n N 3 independent experiments. In B2 and C2, the results are
mean ± SD values obtained frommany pictures that were analyzed, where the results of GFP-CCL2WT−expressing cells were given the
value of 1. Throughout the figure, *P b .05 and ***P b .001 comparing GFP-CCL2 WT and GFP-CCL2-R18A+K19A. Table 2 provides a
summary of all the results presented in the figure.
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Table 2. Characteristics of Secretion, Golgi Localization and ER Localization of GFP-CCL2 WT
and GFP-CCL2 Mutants Following Expression in MDA-CCL2-Low Cells.
CCL2 Mutant % Inhibition
of secretion ± SD
versus
GFP-CCL2 WT
Fold Golgi
localization
versus GFP-CCL2
WT (% Inhibition)
Fold ER
localization
versus
GFP-CCL2 WT
GFP-CCL2-R18A+K19A 51.1% ± 13.7 0.41 (59%) 1.62
GFP-CCL2-R24A 85.6% ± 2.3 0.45 (55%) 1.67
GFP-CCL2-H66A 46.1% ± 15.8 1.01 (0%) 1.02
GFP-CCL2-TIVA−− 70.2% ± 4.3 0.37 (63%) 1.43
GFP-CCL2-R18A+K19A+TIVA−− 93.3% ± 9.3 0.4 (60%) 1.73
The table summarizes the results of Figures 5 to 9 on inhibition levels of CCL2 secretion by breast
tumor cells, presented as mean ± SD of the results obtained for each mutant in at least n = 3
independent experiments. In addition, the table summarizes the data presented in Figures 5 to 9 on
Golgi and ER localization of each mutant compared to the WT chemokine. The results on Golgi
and ER localization are based on analyses of many pictures that were taken in n N 3 independent
experiments, where the values of GFP-CCL2 WT were given the value of 1.
732 CCL2 secretion: GAGs and chemokine motifs Lebel-Haziv et al. Neoplasia Vol. 16, No. 9, 2014promotes pro-malignancy activities at the tumor microenvironment and in
the cancer cells and contributes to increased tumor growth and progression.
In this study, we have identified key regulatory events that control
the process of CCL2 secretion by breast tumor cells (Scheme W1).
We have shown that GAGs, specifically HS and CS, partly mediate
the shuttling of CCL2 toward secretion and have pinpointed CCL2
domains that control its secretion. We have also identified the stages
along the ER-to-Golgi trafficking process through which each domain
may regulate the CCL2 secretion process, as will be described below.
Our findings suggest that specific CCL2 domains regulate the
secretion process by interacting with intracellular GAGs and/or with
other intrinsic components and indicate that CCL2 secretion is
controlled at many different stages along the secretory path.
Below, we describe the novel findings revealed in this study, their
contribution to thewaywe conceive themechanisms regulating chemokine
secretion, and their implications to potential points of intervention in
cancer in general (see also Conclusions section).
1. Intracellular GAGs in general, and HS and CS in
particular, constitute an important mechanism that mediates
the secretion of CCL2.
This conclusion is supported by many of the experimental
approaches taken in the study, including the comparisons of CCL2
WT secretion by CHO-GAG+++ and CHO-deficient GAG cells, the
experiments in which HS and CS were downregulated by shRNAs (to
EXT2 and CHSY1), and the secretion phenotypes of CCL2 variants
mutated in GAG-binding domains. Further below, we discuss the
overall implications of GAG roles in secretion, particularly of
chemokines, but we also wish to point out that based on our results
GAGs are only partly involved in the process of CCL2 secretion. The
question is therefore which other cellular components regulate CCL2
release by the cells. On the basis of the fact that there is an overlap
between the GAG-binding motifs and CCR2b-binding domains of
CCL2 (e.g., amino acids R24 and K49, binding CCR2 as monomers
[51,66]), we inquired in the study also the possibility that the main
CCL2 receptor, CCR2b, mediates the secretion of CCL2 by the cells.
To analyze this possibility, we determined the secretion levels of GFP-
CCL2 WT by native HEK 293 cells that do not express CCR2b
endogenously, compared to CCR2b-overexpressing HEK 293 cells.
We found that CCR2b overexpression did not lead to up-regulation
of CCL2 WT secretion but rather the experiments suggested that the
receptor may trap the secreted chemokine and lead to its
internalization (data not shown). These experiments pointed to
more complex mechanisms than initially expected, and they will haveto be followed by designated studies that would address the roles of
CCR2b in regulating the extracellular levels of CCL2 and the roles of
different CCL2 domains in its internalization by CCR2b.
2. In the process of CCL2 secretion, GAGs affect the step in
which the chemokine is directed from the Golgi toward secretion.
This conclusion is made based on the fact that CCL2 has normally
reached the Golgi apparatus in CHO-deficient GAG cells, but
nevertheless, its secretion was inhibited by 59.4 ± 16.2% in these
cells. This finding agrees well with the fact that the key steps of GAG
synthesis—including HS and CS—take place in the Golgi [63–65].
The implications of this finding are that CCL2 reaches the Golgi in a
GAG-independent process and moves from the Golgi toward
secretion in a process that is GAG-dependent.
3. The process of CCL2 secretion is regulated by multiple
CCL2 domains, including typical GAG-binding domains and the
40s loop.
Our findings indicate that CCL2 secretion by breast tumor cells is
coordinated by several chemokine domains. The Golgi and ER
localization phenotypes of the different mutants have also suggested
that each domain contributes its share to specific steps of the ER-to-
Golgi-secretion route taken by the chemokine (Scheme W1).
Below, we propose our interpretations of the roles played by each
CCL2 domain in these processes. As a word of caution, we would like
to mention that elevated ER localization of some of the mutants could
have been not only due to the roles of CCL2 domains in ER-to-Golgi
trafficking but also because of “saturation” of the secretory pathway or
some folding issues. Yet, we would like to note that 1) all mutants
were compared to the WT form of the chemokine that provides the
background levels of ER localization, under conditions in which the
chemokine occupies the secretory pathway to its outmost levels
(because it is the WT form that is highly secreted); 2) our WB
analyses indicated that all CCL2 mutants had the correct MW and
the bioinformatics studies suggested that all mutants had intact
structure. Correct folding of the mutants was greatly supported by the
published NMR analyses, demonstrating correct 3D structure of all
the GAG-binding mutants used in our study.
Taking all the above considerations into account, we wish to
address first the regulation of CCL2 secretion and intracellular
trafficking by the GAG-binding domains of CCL2. In this study, we
have addressed the GAG-binding domains R18+K19, R24 and H66.
Our analyses suggest that each of these domains participates in
definite, and not necessarily overlapping, stages of the process: 1) H66
—The secretion of GFP-CCL2-H66A was inhibited by 46.1% in
breast tumor cells. Since the chemokine has reached normally the
Golgi in these cells, its reduced secretion must have been the result of
it lower ability to proceed from the Golgi toward secretion. As
discussed above, we have shown that the GAG-dependent process of
CCL2 secretion is the post-Golgi stage. Thus, we suggest that H66
mediates the interaction of CCL2 WT with GAGs that shuttle the
chemokine from the Golgi toward secretion; 2) R24—Mutation in
R24 (GFP-CCL2-R24A) has led to 85.6% inhibition of CCL2
secretion, accompanied by only 55% reduction in its ability to reach
the Golgi in breast tumor cells. Thus, the R24A-mutated chemokine
could partly proceed to the Golgi, but those molecules that reached
the Golgi did not fully traffic toward secretion. This means that the
R24 aa regulates two steps of the secretion process: the GAG-
dependent phase of Golgi to secretion and the GAG-independent
stage of ER-to-Golgi trafficking. The previous identification of R24 as
a major GAG-binding domain of CCL2 suggests that R24 mediates
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Figure 6. The secretion of GFP-CCL2-R24A by breast tumor cells is almost completely inhibited, and the mutated chemokine shows
reduced propensity for Golgi localization. MDA-CCL2-low cells were transfected to express GFP-CCL2 WT or GFP-CCL2-R24A. Similar
expression levels of GFP-CCL2-R24A compared to GFP-CCL2 WT were validated by FACS analyses (Figure W5B). All additional details
(including number of repeats and modes of data presentation) are similar to those of Figure 5, albeit with the GFP-CCL2-R24A mutant.
Throughout the figure, ***P b .001 comparing GFP-CCL2 WT and GFP-CCL2-R24A. Bar, 10 μm. Table 2 provides a summary of all the
results presented in the figure.
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also regulate the step of ER exit, possibly by binding to non-GAG
components that control the trafficking of the chemokine from the
ER to the Golgi; 3) R18+K19—The double mutant GFP-CCL2-
R18A+K19A has shown 51.1% inhibition in secretion and similar
levels of reduction in Golgi localization in breast tumor cells. These
findings indicate that the inhibition of the R18A+K19A mutant
takes place at the ER-to-Golgi stage that is the non–GAG-dependentstep of CCL2 shuttling toward secretion. Therefore, despite its being
a GAG-binding domain, the R18+K19 region probably regulates the
non–GAG-dependent stage of ER-to-Golgi mobilization.
To follow on the above, the analyses of the 40s loop have
indicated that the 45TIVA48 sequence, alone or in combination
with the R18+K19 motif, plays distinct roles in regulating CCL2
secretion and intracellular trafficking: 1) The 45TIVA48 sequence—
The secretion of the GFP-CCL2-TIVA−− mutant was inhibited by
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Figure 7. The secretion of GFP-CCL2-H66A by breast tumor cells is partly inhibited, and the mutated chemokine shows normal Golgi and
ER localization. MDA-CCL2-low cells were transfected to express GFP-CCL2 WT or GFP-CCL2-H66A. Similar expression levels of GFP-
CCL2-H66A compared to GFP-CCL2WTwere validated by FACS analyses (FigureW5C). All additional details (including number of repeats
andmodes of data presentation) are similar to those of Figure 5, albeit with the GFP-CCL2-H66Amutant. Throughout the figure, **P b .01
comparing GFP-CCL2WT and GFP-CCL2-H66A. NS, not significant. Bar, 10 μm. Table 2 provides a summary of all the results presented in
the figure.
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reaching the Golgi in breast tumor cells. Thus, the 45TIVA48
domain of CCL2 was required mostly for the ER-to-Golgi step that
is the GAG-independent stage of the process. Indeed, the 45TIVA48
motif is not expected to regulate the process by interacting with
GAGs because it is not one of the GAG-binding domains of CCL2.Rather, the 45TIVA48 stretch probably mediates the interactions of
CCL2 with as yet unidentified other intracellular components that
regulate the exit of the chemokine from the ER. Here, it is
interesting to note that the 40s loop was found in the past to control
the positioning of other chemokines—CCL5, CXCL8 and CXCL4
—in secretory organelles. Only in the case of CCL5 the 40s loop
Figure 8. The secretion of GFP-CCL2-TIVA−− by breast tumor cells is partly inhibited, and the mutated chemokine shows reduced
propensity for Golgi localization. MDA-CCL2-low cells were transfected to express GFP-CCL2 WT or GFP-CCL2-TIVA−−. Similar
expression levels of GFP-CCL2-TIVA−− compared to GFP-CCL2 WT were validated by FACS analyses (Figure W5D). All additional details
(including number of repeats and modes of data presentation) are similar to those of Figure 5, albeit with the GFP-CCL2-TIVA−−mutant.
Throughout the figure, *P b .05 and ***P b .001 comparing GFP-CCL2 WT and GFP-CCL2-TIVA−−. Bar, 10 μm. Table 2 provides a
summary of all the results presented in the figure.
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(43TRKN46); in contrast, most of the aa of the 40s domains of
CXCL8 and CXCL4—44SDG46 in CXCL8 and 45LKNG48 in
CXCL4 [49,50]—are not charged, and indeed, these motifs are not
the GAG-binding domains of these two chemokines. It is possible
that the exposed nature of the 40s loop in all these three latter
chemokines—CCL2, CXCL8, and CXCL4—enables their inter-action with intracellular components that direct the positioning of
these chemokines in secretory organelles; 2) The 45TIVA48
sequence combined with the R18+K19 motif—The R18A+K19A
+TIVA−− mutant has shown an interesting phenotype, in which its
secretion was almost completely inhibited in breast tumor cells
(93.3%), but its Golgi localization was reduced by 60% only. Thus,
this double mutant may interact with intracellular components that
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Figure 9. The secretion of GFP-CCL2-R18A+K19A+TIVA−− by breast tumor cells is completely inhibited, and the mutated chemokine
shows reduced propensity for Golgi localization. MDA-CCL2-low cells were transfected to express GFP-CCL2 WT or GFP-CCL2-R18A
+K19A+TIVA−−. Similar expression levels of GFP-CCL2-R18A+K19A+TIVA−− compared to GFP-CCL2 WT were validated by FACS
analyses (Figure W5E). All additional details (including number of repeats and modes of data presentation) are similar to those of Figure 5,
albeit with the GFP-CCL2-R18A+K19A+TIVA−−mutant. Throughout the figure, **P b .01 and ***P b .001 comparing GFP-CCL2WT and
GFP-CCL2-R18A+K19A+TIVA−−. Bar, 10 μm. Table 2 provides a summary of all the results presented in the figure.
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Golgi, as well. It is possible that in this double mutant, each domain
has assumed the ability to regulate a separate stage of the process or
alternatively that there was an overlap in which each of the two
domains similarly regulated the process.The results obtained in our study also suggest that there may be
combinatorial effects to different CCL2 motifs in regulating the
secretion process of the chemokine. CCL2 tetramers are those that
most efficiently bind extracellular GAGs. If such tetramers are
formed intracellularly, then the domains that we have identified may
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Figure 10. The general use of CCL2 GAG-binding domains and its 40s loop by different cell types. CHO-GAG+++ cells (A) and HEK 293
cells (B) were transfected to express GFP-CCL2 WT or GFP-CCL2 mutants: GFP-CCL2-R18A+K19A, GFP-CCL2-R24A, GFP-CCL2-H66A,
GFP-CCL2-TIVA−−, and GFP-CCL2-R18A+K19A+TIVA−−. Similar expression levels of the WT and mutated variants of CCL2 were
validated by FACS analyses (Figure W6 for CHO-GAG+++ cells and Figure W7 for HEK 293 cells). The levels of CCL2 in cell supernatants
were determined 48 hours following transfection by sandwich ELISAs, at the linear range of absorbance. *P b .05, **P b .01 and
***P b .001 for GFP-CCL2 mutants compared to GFP-CCL2WT. NS, not significant. The results are representatives of n ≥ 3 independent
experiments. Table 3 provides a summary of all the results.
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trafficking process of CCL2 toward secretion. For example, it is
possible that in the tetramer there will be cooperativity between H66
that controls the GAG-dependent post-Golgi stage and R24 that
controls the non–GAG-dependent ER-to-Golgi step. The results
obtained above with the R18A+K19A+TIVA−− mutant strongly
support such cooperativity between the different CCL2 domains.
This combined mutant has acquired a phenotype that was similar
(regulating the ER-to-Golgi stage) but also partly extended
(regulating the Golgi-to-secretion stage) when compared to each
single mutant (R18A+K19A or TIVA−−). Therefore, it is possible
that when the R18+K19 motif was joined by the 45TIVA48 domain,its GAG-binding activities have enabled it to mediate also the GAG-
dependent stage of Golgi toward secretion.
Overall, we have identified CCL2 domains that regulate its
secretion and intracellular trafficking and have demonstrated key,
although partial, roles for intracellular GAGs in the process.
Conclusions
The findings of our study shed light on the complexity of the process
that transports CCL2 toward secretion and set an important role to
GAGs in this process. These observations add to our current
understanding of the way GAGs affect different cellular processes.
Several recent studies have suggested that intracellular GAGs have key
Table 3. The Secretion Levels of GFP-CCL2 WT and GFP-CCL2 Mutants by CHO-GAG+++
Cells and HEK 293 Cells.
CCL2 Mutant CHO-GAG+++ Cells:
% Inhibition of
Secretion ± SD
versus GFP-CCL2 WT
HEK 293 Cells:
% Inhibition of
Secretion ± SD
versus GFP-CCL2 WT
GFP-CCL2-R18A+K19A 46.9 ± 32 19.7 ± 13.4
GFP-CCL2-R24A 72.3 ± 13.4 69.6 ± 12.1
GFP-CCL2-H66A 36.9 ± 13 19.4 ± 4.8
GFP-CCL2-TIVA−− 59.6 ± 17.5 69.7 ± 7.8
GFP-CCL2-R18A+K19A+TIVA−− 84.8 ± 3 86.6 ± 9.4
The table summarizes the results of Figure 10 on inhibition levels of CCL2 secretion by CHO-
GAG+++ cells and HEK 293 cells. For each mutant, the mean ± SD values were obtained from at
least n = 3 independent experiments, calculated compared to GFP-CCL2 WT.
738 CCL2 secretion: GAGs and chemokine motifs Lebel-Haziv et al. Neoplasia Vol. 16, No. 9, 2014roles in delivering proteins to the cell membrane or to the extracellular
milieu of cells [70]. Functional interactions with HS proteoglycans
were shown to be essential for the export of FGF-2, and HS was also
found to be involved in insulin secretion [71,72]. Specifically for
chemokines, our current research on CCL2 extends several previous
studies that addressed the roles of GAGs and GAG-binding domains
of chemokines in secretion: The first was our published study that has
identified the GAG-binding 40s domain of CCL5 and GAGs as
essential components required for its secretion [44]; the second was
the study by Luster and colleagues showing that cytotoxic T cells
secreted CCL5, CCL3 and CCL4 as macromolecular complexes
containing sulfated proteoglycans [73]. Another related publication
indicated that the core protein of serglycin is involved in the secretion
of CXCL1 by endothelial cells [74]. Overall, there is a growing body
of evidence suggesting key roles for GAGs in regulating secretory
processes, and in the case of chemokines, this activity agrees well with
the major role of GAGs in presenting chemokines to leukocytes,
promoting their transendothelial migration to inflamed tissues.
On the basis of our results in this study, we propose that the
secretion of CCL2 by breast tumor cells and consequently the tumor-
promoting activities of this chemokine could be inhibited by
modalities that would target the interactions of CCL2 with
intracellular components. Here, a most intriguing candidate is R24,
a single aa that has an essential role in regulating CCL2 secretion in
breast tumor cells but also in other cell types, suggesting that the
intracellular component/s binding this aa are shared by many cell
types. Therefore, it is expected that modalities targeting CCL2
domains, particularly R24 (through measures that we have already
started to design), may be effective not only in breast tumor cells but
may also inhibit the secretion of this tumor-promoting chemokine by
other cells of the tumor microenvironment, leukocytes and stroma
cells alike.
Such a possible strategy of CCL2 inhibition can lead to reduced
expression of the chemokine in breast tumors; this may apply to other
malignancies as well, because CCL2 is considered as a tumor-
promoting factor in many cancer diseases [5–14]. The question is
whether such modalities will impact the ability of the host to mount
inflammatory processes in response to infection. Our assumption is
that they will not, because of the high redundancy that characterizes
the chemokine superfamily, suggesting that several other chemokines
could take over the missing activities of CCL2 and induce monocyte
and T cell migration in times of infection. One of them is CCL5,
whose mechanism of secretion depends on the 43TRKN45 motif and
not on R24 or any of the other domains required for CCL2 secretion,
and thus, CCL5 is not expected to be affected by inhibitory measuresdirected against chemokine sequences that regulate the secretion
of CCL2.
To conclude, we propose that the observations made in our study
open novel avenues for CCL2 inhibition that may target its activities in
cancer while not threatening the overall immune integrity of the host.
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